DLA Piper advises Finnish group Medix Biochemica on the acquisition of Diaclone

DLA Piper has advised Medix Biochemica, a global leader in critical raw materials for the in vitro diagnostics (IVD) industry, on the acquisition of Diaclone from Biotech Investissement Group. As a result of the acquisition, Medix Biochemica broadens its portfolio of critical raw materials for the IVD industry, complements its scientific expertise and strengthens its local presence in Western Europe.

Medix Biochemica is a Finnish biotechnology company focusing on high quality raw materials and diagnostic tests for global markets. It develops, produces and markets antibodies, antigens and antibody services for the IVD industry and point-of-care tests for healthcare professionals.

Founded in 1986, Diaclone is widely recognized for its expertise in the fields of inflammation, oncology and immunology. The company offers best-in-class monoclonal antibodies, high quality ELISA and ELISpot kits as well as custom services – ranging from immunoassay kit development to new antibody discovery using hybridoma and phage display technologies – to a broad range of IVD, life science, and pharma customers.

The DLA Piper Corporate team in Paris was led by partner Sarmad Haidar and senior associate Anthony Guillaume. Biotech Investissement group was advised by law firm Franklin with a team led by partner Yam Atallahand and associate Vincent Lehmann.